Birgitta Grundmark

Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations

Ola Caster, Yasunori Aoki, Lucie M. Gattepaille et al. · Drug Safety · 2020 · 168 citations · Full text

Pharmacy, Biostatistics, Pharmacology +17

The Metabolic Syndrome and the Risk of Prostate Cancer under Competing Risks of Death from Other Causes

Birgitta Grundmark, Hans Garmo, Massimo Loda et al. · Cancer Epidemiology Biomarkers & Prevention · 2010 · 77 citations · Full text

Medicine, Biostatistics, Oncology +17

Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer

Christel Häggström, Mieke Van Hemelrijck, Björn Zethelius et al. · International Journal of Cancer · 2016 · 69 citations · Full text

Medicine, Oncology, Urology +16

Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area

Birgitta Grundmark, Lars Holmberg, Hans Garmo et al. · European Journal of Clinical Pharmacology · 2014 · 67 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +16

Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre

Sarah Watson, Rebecca E. Chandler, H. Taavola et al. · Drug Safety · 2017 · 56 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +16